Presentation is loading. Please wait.

Presentation is loading. Please wait.

At the forefront of Immunotherapy OTCQB: TPIV 1551 Eastlake Ave E Suite 100 Seattle, WA www.TapImmune.com.

Similar presentations


Presentation on theme: "At the forefront of Immunotherapy OTCQB: TPIV 1551 Eastlake Ave E Suite 100 Seattle, WA www.TapImmune.com."— Presentation transcript:

1 At the forefront of Immunotherapy OTCQB: TPIV 1551 Eastlake Ave E Suite 100 Seattle, WA www.TapImmune.com

2 CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company's plan of operations and finances, the potential for the Company's vaccines and proposed clinical trials. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.

3 Opportunity & Milestones Why invest in TapImmune now? Immunotherapy is the fastest growing pharmaceutical sector Unique and broad product opportunities in cancer & infectious disease Technology platforms: Comprehensive approach to T-cell stimulation PolyStart™ is a significant advance in vaccine design Two Phase I Clinical Trials ready to progress to Phase II HER2/neu breast cancer vaccine potential blockbuster Ovarian cancer vaccine addresses urgent therapeutic need “A” team of management and advisors Series of preclinical and clinical value inflexion points Undervalued - poised for significant growth – great buying opportunity

4 TAPIMMUNE INC. Immunotherapy is the new frontier in cancer therapy Human immune system is largest manufacturer of therapeutic molecules Immunotherapy enhances the immune system to identify, fight and eradicate disease TapImmune has the leading and most comprehensive approach to stimulate T-cells and enhance antigen presentation Applicable to cancer (including metastatic disease) and infectious disease across broad patient populations Simple injectable products

5 Immunotherapy Landscape Monoclonal Antibodies: Herceptin (tratuzumab); Perjeta (pertuzumab) Keytruda (pembrolizamab); Yervoy (ipilimumab) T-cell Stimulation – Ex Vivo: T-Cell Transfer: Lion, Juno, Kite Dendritic Cell Transfer: Dendreon, NW Bio, Prima BioMed T-cell Stimulation – In Vivo Antigen Approaches: ONTY, GALE, IMUC Antigens + Antigen Presentation: TPIV Marketed Products: Provenge; Gardasil; Keytruda; Yervoy, Herceptin

6 TapImmune Technologies Stimulate four important functions in the immune system T-CellFunctionTechnology* T-killer cells (CTLs;CD8)Kill non-self cellsPeptide antigens Polystart™ T-helper cells (CD4)Release cytokines Activate and grow T-killer cells Peptide antigens Polystart™ T-memory cells5-10% of activated T-cells have long-term memory for antigen Peptide antigens Antigen PresentationTransport foreign antigens to cell surface – inhibited in many tumor cells TAP Polystart™ Peptide antigens & Polystart™ used together as a “Prime” and “Boost” strategy *Science published in over 20 peer-reviewed publications

7 Product Pipeline

8 Lead Product TPIV 100/110: HER2/neu Breast Cancer HER2/neu is overexpressed in ~ 30% breast cancer patients (total 220,000 /yr) Roche’s monoclonal antibody, Herceptin (current standard of care) can only treat ~ 20% of these patients (+$6 billion sales in 2013) Herceptin does not stimulate Killer T-cells – it slows/retards tumor growth Potential for TPIV’s vaccine to: provide long lasting immune response in up to 84% of the HER2/neu positive patient population. Ability to kill tumor cells and treat metastatic disease

9 TPIV 100 Clinical Status Her2neu Breast Cancer - Mayo Clinic Rochester MN Class II antigens (TPIV 100: 4 antigens) discovered in breast cancer patients - Clin. Cancer Res. (2010) 16, 825-83 22 Patients post Herceptin 6 x monthly intradermal + GMCSF Well tolerated Safety and Immune responses on all patients Trial successful and vaccine stimulates immune system as predicted Phase l

10 TPIV 100/110 Clinical Status Class II + Class I antigens Clinical team & multiple clinical centers identified 150-300 patient study Manufacturing & formulation underway Clinical protocol in final review (statistician; breast cancer experts) Pre IND request ready for submission PreIND meeting and IND filing in Q1-Q2, 2015 Collaboration with VGTI Florida announced Phase ll:

11 TPIV 110 +TPIV 100 The leading HER2/neu technology platform in clinical development Discovery in lab of Dr Keith Knutson (Mayo) T-killer cell antigen (p373-382: TPIV110) licensed from Mayo Clinic 4-5x greater killing activity against human breast cancer cells than NeuVax (E-75 from Galena) Work published in J. Immunol. (2013) 190, 479-488

12 TPIV200 – Folate Receptor Alpha Antigens Ovarian & Breast Cancer Folate Receptor Alpha is expressed over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy Also expressed in Triple Negative Breast Cancer Urgent clinical need for a new therapeutics. Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence. US alone, approximately 30,000 ovarian cancer patients newly diagnosed every year. Orphan Drug Application $ Multi-Billion product potential

13 TPIV 200 Clinical Status Stage II/IIl Ovarian & Breast Cancer - Mayo Clinic MN 22 patients with Stage II-III Breast, Ovarian, Peritoneal, Fallopian Tube Cancer Interim safety checkpoint completed Positive Immune responses observed Promising Interim Results – Support progression to Phase ll Pre-IND Phase ll meeting Q1 2015 Phase ll Expected to Start in Q1-Q2 2015 with Orphan Drug Application

14 PolyStart ™ DNA Expression Vector Enhanced synthesis of a peptide antigen array (PAA) comprising multiple proprietary T-cell peptide epitopes Up to 4x conventional protein expression Vaccine technology - rapid plug-and-play design Used with T-cell peptide based immunization strategies (e.g., prime and boost) Can be co-expressed with transporter protein known as TAP1 to unmask hidden antigens Simple and cost-effective manufacturing New IP filed

15 Infectious Disease Platform Technologies with Infinite Opportunities High Global Priority for Vaccine Development for Emerging Threats Ebola, Dengue, West Nile, Bird Flu, Smallpox TAPvax: Smallpox vaccine up to 100 times more effective PolyStart™: Rapid vaccine development for emerging threats TPIV 300: Prototype peptide vaccine for smallpox (Mayo)

16 Collaborators & Scientific Advisors World Class Team Dr Keith Knutson (Vaccine & Gene Therapy Institute of Florida/Mayo Clinic): Director, Cancer Immunology and Immunotherapy Program, VGTI; Adjunct Faculty - Immunology, Mayo Clinic Dr Patrick Yeramian (Vaccine & Gene Therapy Institute of Florida) Medical Director Dr Greg Poland: (Mayo Clinic) Head of Vaccines; Infectious disease/biodefense Dr Mac Cheever (Fred Hutchinson Cancer Research Center) Director Solid Tumor Research; Professor of Medicine/Oncology at the University of Washington (Seattle) & Director of the NCI-funded Cancer Immunotherapy Trials Network (CITN)

17 Management And Advisors Mark Reddish Advisor: Development, Board 25 years experience in cancer vaccines and biodefense Biomira, ID Biomedical, Baxter, Bayer AG Denis Corin Corporate Finance Beckman Coulter, Novartis, MIV Therapeutics, Business Objects (PeopleSoft) Glynn Wilson, PhD CEO 25 years experience in product & corporate development SmithKline Beecham, Ciba-Geigy, Tacora Bob Florkiewicz, PhD Head of Research 25 years experience, academic and biotech Synergen, TSRI, UW, GSK, Seed IP Law Group

18 Cap Structure and Comps Reorganized Feb 2014 TPIV - TAPIMMUNE INC Capital Structure Shares Outstanding19,603,815 Public Float8,000,000 Market cap ~$8,000,000 Stock Price$0.40 Comparisons in Immunotherapy and Biotech Shares OutMarket Cap Stock Price GALE (Galena)105,240,000$ 250,000,000 $2.50 LBIO (Lion Bio)26,000,000$ 180,000,000 $6.50 INO (Inovio)60,000,000$ 565,550,000 $10.30 DNDN (Dendreon)160,000,000$ 160,000,000 $1.00 NWBO (Nothwest Bio)53,400,000$ 355,730,000 $5.95

19 Opportunity & Milestones Why invest in TapImmune now? Immunotherapy is the fastest growing pharmaceutical sector Unique and broad product opportunities in cancer & infectious disease Technology platforms: Comprehensive approach to T-cell stimulation PolyStart™ significant advance in vaccine design Two Phase I Clinical Trials ready to progress to Phase II HER2/neu breast cancer vaccine potential blockbuster Ovarian cancer vaccine addresses urgent therapeutic need “A” team of management and advisors Series of preclinical and clinical value inflexion points Undervalued - poised for significant growth – great buying opportunity

20 TAPIMMUNE VISION Immunotherapy will lead the fight against cancer Combination therapies will include monoclonal antibodies and T-cell therapies TapImmune has positioned itself to be the leader in comprehensive in vivo T-cell therapies

21 THANK YOU CONTACT: GLYNN WILSON Chief Executive Officer gwilson@tapimmune.com OTCBB: TPIV


Download ppt "At the forefront of Immunotherapy OTCQB: TPIV 1551 Eastlake Ave E Suite 100 Seattle, WA www.TapImmune.com."

Similar presentations


Ads by Google